RLFTF - Relief NRx extend time to settle litigation over COVID-19 therapy aviptadil

• Relief Therapeutics ( OTCQB:RLFTF ) ( OTCQB:RLFTD ) and NRx Pharmaceuticals ( NASDAQ: NRXP ) extended the stay of their pending litigation until Nov. 11 to get more time to finalize a settlement.
• The companies have been embroiled in litigation over experimental COVID-19 therapy Zyesami (aviptadil) and in August agreed to discuss a tentative settlement.
• Relief on Tuesday said that while  the parties are far along in their negotiation of settlement documents, no final agreements have been reached and there can be no assurance that a proposed settlement will be successfully completed.
• In April, Relief had said that it entered a stipulation to stay the proceedings in its pending litigation with NRx's unit NeuroRx, and Jonathan Javitt to allow the parties to attempt to seek to mediate their dispute.
• NRXP +7.35% to $0.95 premarket Nov. 8

For further details see: